Acaluxen Capsule

About Acaluxen 100 mg Capsule

Acaluxen, from Everest Pharmaceuticals Ltd., contains acalabrutinib 100 mg in capsule form. It is a targeted medicine used for certain blood cancers in adults, and a specialist doctor decides if it is suitable.

What is Acaluxen 100 mg Capsule?

Acaluxen is a brand of acalabrutinib, a tyrosine kinase inhibitor made by Everest Pharmaceuticals Ltd. It comes as 100 mg capsules. Acalabrutinib works by blocking a protein called BTK that helps some cancer cells grow and survive. It is used in adults for mantle cell lymphoma after at least one earlier treatment, and for chronic lymphocytic leukaemia or small lymphocytic lymphoma. Because it is a specialist cancer medicine, only a qualified doctor can decide whether it is right for a particular person. The dose, course and any changes are set by the doctor, not by the patient.

Uses of Acaluxen

Acaluxen is used in adults to treat mantle cell lymphoma when at least one other treatment has already been given. It is also used for chronic lymphocytic leukaemia and small lymphocytic lymphoma. It belongs to a group of medicines called kinase inhibitors, which target specific proteins inside cancer cells. It is not a general-purpose medicine and should only be used under the care of a cancer specialist. Ask the doctor for details about how it fits into your treatment plan.

How to use Acaluxen

Acaluxen capsules are swallowed whole with water and should not be broken, opened or chewed. The doctor decides the dose and how long the course lasts, and may change the schedule based on how you respond and any side effects. Do not adjust the dose yourself. Tell your doctor about all other medicines you take, because some medicines can interact with acalabrutinib. If you miss a dose, ask your doctor or pharmacist what to do rather than guessing.

Side effects of Acaluxen

Common side effects include low red blood cell counts (anaemia), low white cell counts (neutropenia), low platelet counts, upper respiratory tract infection, headache, diarrhoea and pain in muscles or bones. Some people may have more serious problems such as infections, bleeding, heart rhythm changes or other cancers. Tell your doctor promptly about any unusual bleeding, fever, signs of infection, or a racing or irregular heartbeat. The doctor will arrange regular blood tests and monitor you during treatment.

Safety and precautions

Acaluxen can cause serious infections, bleeding, low blood counts and heart rhythm problems, so regular monitoring is needed. It may harm an unborn baby; pregnancy should be avoided during treatment, and effective contraception should be discussed with the doctor. It is not known whether acalabrutinib passes into breast milk, so breastfeeding should be discussed with the doctor. Before starting, tell your doctor if you are pregnant or breastfeeding, have liver problems, take other medicines, or have had bleeding or heart problems. The doctor will decide if it is safe for you.

Frequently asked questions

What is Acaluxen and what is it used for?

Acaluxen contains acalabrutinib, a kinase inhibitor. It is used in adults for mantle cell lymphoma after at least one earlier treatment, and for chronic lymphocytic leukaemia or small lymphocytic lymphoma. Only a specialist doctor can decide if it is suitable for you.

How should I take Acaluxen capsules?

Swallow the capsule whole with water; do not break, open or chew it. The doctor decides the dose, how often to take it and how long the course lasts, and may adjust it. Never change the dose yourself without speaking to your doctor.

Is Acaluxen safe during pregnancy or breastfeeding?

Acaluxen may harm an unborn baby. There is no information on whether it passes into breast milk, so breastfeeding is not advised unless your doctor says otherwise. Tell your doctor if you are pregnant, planning pregnancy or breastfeeding.

What is the price of Acaluxen?

The listed price is ৳ 1000.00.

Indications

Acaluxen is a kinase inhibitor indicated for the treatment of adult patients with:
  • Mantle cell lymphoma (MCL) who have received at least one prior therapy
  • This indication is approved under accelerated approval based on overall response rate Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials
  • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Pharmacology

Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibited BTK-mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and tumor growth in mouse xenograft models.

Dosage & Administration

The recommended dose of Acalabrutinib is 100 mg taken orally approximately every twelve hours until disease progression or unacceptable toxicity. Advise patients to swallow capsule whole with water. Advise patients not to open, break or chew the capsules. Acalabrutinib may be taken with or without food. If a dose of Acalabrutinib is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra capsules of Acalabrutinib should not be taken to make up for a missed dose.

Recommended Dose Modifications for Adverse Reactions: Dosage of Acalabrutinib can be reduced up to 100 mg daily for the toxicity has resolved to Grade 1 or baseline level. If the adverse reaction occurrence more than four times Acalabrutinib can be Discontinue.

Interaction

Effect of CYP3A Inhibitors on Acaluxen: Co-administration with a strong CYP3A inhibitor (200 mg Iitraconazole once daily for 5 days) increased the Acaluxen Cmax by 3.9-fold and AUC by 5.1-fold in healthy subjects. Physiologically based pharmacokinetic (PBPK) simulations with Acaluxen and moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem) showed that co-administration increased Acaluxen Cmax and AUC increased by 2- to almost 3-fold.

Effect of CYP3A Inducers on Acaluxen: Co-administration with a strong CYP3A inducer (600 mg rifampin once daily for 9 days) decreased Acaluxen Cmax by 68% and AUC by 77% in healthy subjects.

Gastric Acid Reducing Agents: Acaluxen solubility decreases with increasing pH. Co-administration with an antacid (1 g calcium carbonate) decreased Acaluxen AUC by 53% in healthy subjects. Co-administration with a proton pump inhibitor (40 mg omeprazole for 5 days) decreased Acaluxen AUC by 43%.

In Vitro Studies-
Metabolic Pathways: Acaluxen is a weak inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but does not inhibit CYP1A2, CYP2B6, CYP2C19, and CYP2D6. The active metabolite (ACP-5862) is a weak inhibitor of CYP2C8, CYP2C9 and CYP2C19, but does not inhibit CYP1A2, CYP2B6, CYP2D6 and CYP3A4/5. Acaluxen is a weak inducer of CYP1A2, CYP2B6 and CYP3A4; the active metabolite (ACP-5862) weakly induces CYP3A4. Based on in vitro data and PBPK modeling, no interaction with CYP substrates is expected at clinically relevant concentrations.

Drug Transporter Systems: Acaluxen is a substrate of P-glycoprotein (P-gp) and BCRP. Acaluxen is not a substrate of renal uptake transporters OAT1, OAT3, and OCT2, or hepatic transporters OATP1B1, and OATP1B3. Acaluxen does not inhibit P-gp, OAT1, OAT3, OCT2, OATP1B1, and OATP1B3 at clinically relevant concentrations. Acaluxen may increase exposure to co-administered BCRP substrates (e.g., methotrexate) by inhibition of intestinal BCRP.

Side Effects

Most common adverse reactions (incidence ≥30%) were: anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.

Pregnancy & Lactation

Pregnancy: Based on findings in animals, Acalabrutinib may cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of Acalabrutinib to pregnant rabbits during organogenesis resulted in reduced fetal growth at maternal exposures (AUC) approximately 4 times exposures in patients at the recommended dose of 100 mg twice daily. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Lactation: No data are available regarding the presence of Acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production. Acalabrutinib and its active metabolite were present in the milk of lactating rats. Due to the potential for adverse reactions in a breastfed child from Acalabrutinib, advise lactating women not to breastfeed while taking Acalabrutinib and for at least 2 weeks after the final dose.

Precautions & Warnings

Hemorrhage: Serious hemorrhagic events, including fatal events, have occurred in the combined safety database of 612 patients with hematologic malignancies treated with Acaluxen monotherapy. Grade 3 or higher bleeding events, including gastrointestinal, intracranial, and epistaxis have been reported in 2% of patients. Overall, bleeding events including bruising and petechiae of any grade occurred in approximately 50% of patients with hematological malignancies. The mechanism for the bleeding events is not well understood. Acaluxen may further increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and patients should be monitored for signs of bleeding. Consider the benefit-risk of withholding Acaluxen for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infection: Serious infections (bacterial, viral or fungal), including fatal events and opportunistic infections have occurred in the combined safety database of 612 patients with hematologic malignancies treated with Acaluxen monotherapy. Consider prophylaxis in patients who are at increased risk for opportunistic infections. Grade 3 or higher infections occurred in 18% of these patients. The most frequently reported Grade 3 or 4 infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation and progressive multifocaln leukoencephalopathy (PML) have occurred. Monitor patients for signs and symptoms of infection and treat as medically appropriate.

Cytopenias: In the combined safety database of 612 patients with hematologic malignancies, patients treated with Acaluxen monotherapy experienced Grade 3 or 4 cytopenias, including neutropenia (23%), anemia (11%) and thrombocytopenia (8%) based on laboratory measurements. In the Acaluxen clinical Trial LY-004, patients’ complete blood counts were assessed monthly during treatment.

Second Primary Malignancies: Second primary malignancies, including non-skin carcinomas, have occurred in 11% of patients with hematologic malignancies treated with Acaluxen monotherapy in the combined safety database of 612 patients. The most frequent second primary malignancy was skin cancer, reported in 7% of patients. Advise protection from sun exposure.

Atrial Fibrillation and Flutter: In the combined safety database of 612 patients with hematologic malignancies treated with Acaluxen monotherapy, atrial fibrillation and atrial flutter of any grade occurred in 3% of patients, and Grade 3 in 1% of patients. Monitor for atrial fibrillation and atrial flutter and manage as appropriate.

Storage Conditions

Do not store above 30⁰C. Keep away from light and out of the reach of children.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.